N-terminal pro-B-type natriuretic peptide in patients with growth hormone disturbances

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

N-terminal pro-B-type natriuretic peptide in patients with growth hormone disturbances. / Andreassen, Mikkel; Faber, Jens; Vestergaard, Henrik; Kistorp, Caroline; Kristensen, Lars Østergaard.

I: Clinical Endocrinology, Bind 66, Nr. 5, 05.2007, s. 619-25.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Andreassen, M, Faber, J, Vestergaard, H, Kistorp, C & Kristensen, LØ 2007, 'N-terminal pro-B-type natriuretic peptide in patients with growth hormone disturbances', Clinical Endocrinology, bind 66, nr. 5, s. 619-25. https://doi.org/10.1111/j.1365-2265.2007.02782.x

APA

Andreassen, M., Faber, J., Vestergaard, H., Kistorp, C., & Kristensen, L. Ø. (2007). N-terminal pro-B-type natriuretic peptide in patients with growth hormone disturbances. Clinical Endocrinology, 66(5), 619-25. https://doi.org/10.1111/j.1365-2265.2007.02782.x

Vancouver

Andreassen M, Faber J, Vestergaard H, Kistorp C, Kristensen LØ. N-terminal pro-B-type natriuretic peptide in patients with growth hormone disturbances. Clinical Endocrinology. 2007 maj;66(5):619-25. https://doi.org/10.1111/j.1365-2265.2007.02782.x

Author

Andreassen, Mikkel ; Faber, Jens ; Vestergaard, Henrik ; Kistorp, Caroline ; Kristensen, Lars Østergaard. / N-terminal pro-B-type natriuretic peptide in patients with growth hormone disturbances. I: Clinical Endocrinology. 2007 ; Bind 66, Nr. 5. s. 619-25.

Bibtex

@article{fd86e135aba544a1ae95c17447a27f8b,
title = "N-terminal pro-B-type natriuretic peptide in patients with growth hormone disturbances",
abstract = "Acromegaly is associated with hypertrophic cardiomyopathy, hypertension and subsequent congestive heart failure. Impairment of cardiac function has also been associated with growth hormone deficiency (GHD). B-type natriuretic peptides (BNPs) have emerged as strong diagnostic and prognostic risk markers. They are cardioprotective hormones that compensate heart disease by promoting natriuresis and modulation of cardiac hypertrophy in response to volume expansion and ventricular wall stretch.",
keywords = "Acromegaly, Adult, Aged, Analysis of Variance, Antineoplastic Agents, Hormonal, Biological Markers, Case-Control Studies, Female, Follow-Up Studies, Growth Hormone, Humans, Insulin-Like Growth Factor Binding Protein 3, Insulin-Like Growth Factor I, Male, Middle Aged, Natriuretic Peptide, Brain, Octreotide, Peptide Fragments, Peptides, Cyclic, Protein Precursors, Retrospective Studies, Somatostatin, Statistics, Nonparametric",
author = "Mikkel Andreassen and Jens Faber and Henrik Vestergaard and Caroline Kistorp and Kristensen, {Lars {\O}stergaard}",
year = "2007",
month = may,
doi = "10.1111/j.1365-2265.2007.02782.x",
language = "English",
volume = "66",
pages = "619--25",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",
number = "5",

}

RIS

TY - JOUR

T1 - N-terminal pro-B-type natriuretic peptide in patients with growth hormone disturbances

AU - Andreassen, Mikkel

AU - Faber, Jens

AU - Vestergaard, Henrik

AU - Kistorp, Caroline

AU - Kristensen, Lars Østergaard

PY - 2007/5

Y1 - 2007/5

N2 - Acromegaly is associated with hypertrophic cardiomyopathy, hypertension and subsequent congestive heart failure. Impairment of cardiac function has also been associated with growth hormone deficiency (GHD). B-type natriuretic peptides (BNPs) have emerged as strong diagnostic and prognostic risk markers. They are cardioprotective hormones that compensate heart disease by promoting natriuresis and modulation of cardiac hypertrophy in response to volume expansion and ventricular wall stretch.

AB - Acromegaly is associated with hypertrophic cardiomyopathy, hypertension and subsequent congestive heart failure. Impairment of cardiac function has also been associated with growth hormone deficiency (GHD). B-type natriuretic peptides (BNPs) have emerged as strong diagnostic and prognostic risk markers. They are cardioprotective hormones that compensate heart disease by promoting natriuresis and modulation of cardiac hypertrophy in response to volume expansion and ventricular wall stretch.

KW - Acromegaly

KW - Adult

KW - Aged

KW - Analysis of Variance

KW - Antineoplastic Agents, Hormonal

KW - Biological Markers

KW - Case-Control Studies

KW - Female

KW - Follow-Up Studies

KW - Growth Hormone

KW - Humans

KW - Insulin-Like Growth Factor Binding Protein 3

KW - Insulin-Like Growth Factor I

KW - Male

KW - Middle Aged

KW - Natriuretic Peptide, Brain

KW - Octreotide

KW - Peptide Fragments

KW - Peptides, Cyclic

KW - Protein Precursors

KW - Retrospective Studies

KW - Somatostatin

KW - Statistics, Nonparametric

U2 - 10.1111/j.1365-2265.2007.02782.x

DO - 10.1111/j.1365-2265.2007.02782.x

M3 - Journal article

C2 - 17492947

VL - 66

SP - 619

EP - 625

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 5

ER -

ID: 92190531